Candel Therapeutics, Inc. filed a Form 8-K on September 10, 2026, disclosing the appointment of Martine Zimmermann, Pharm.D., to its Board of Directors, effective September 8, 2026, and detailing her compensation arrangements.
Key Highlights
- Board expanded: The Board increased in size from ten to eleven directors to accommodate the new appointment.
- New director appointed: Martine Zimmermann, Pharm.D., was unanimously appointed to fill the newly created vacancy, effective September 8, 2026.
- Class III director: Dr. Zimmermann joins the Class III director slate, with her term expiring at the 2027 Annual Meeting of Stockholders.
- Stock option grant: Dr. Zimmermann will receive an option to purchase 64,000 shares of common stock, vesting in equal monthly installments over three years.
- Annual retainer: Dr. Zimmermann will receive a $40,000 annual retainer, paid quarterly in arrears and pro-rated based on actual days served.
- Independence confirmed: The Board determined that Dr. Zimmermann qualifies as an independent director under applicable SEC rules and Nasdaq listing rules.
Candel Therapeutics Adds Regulatory Affairs Executive to Board
According to the filing, the Board of Directors of Candel Therapeutics, Inc. (NASDAQ:CADL) voted on September 6, 2026, to increase its size from ten to eleven members and to appoint Dr. Zimmermann to fill the vacancy created by that expansion. Her appointment became effective September 8, 2026. The Board determined she is an independent director under applicable SEC regulations and Nasdaq Stock Market LLC listing rules.
The filing describes Dr. Zimmermann's current role as Executive Vice President of Regulatory Affairs and Quality Assurance at Inventiva S.A., a position she has held since August 2025. Prior to that, she served as Senior Vice President and Head of Regulatory Affairs at Ipsen Biopharmaceuticals from January 2023 to August 2025, and as Senior Vice President, Head of Global Regulatory and Quality Affairs at Alexion Pharma International from June 2016 to January 2023, having joined Alexion in 2009. The filing states she has worked across all phases of drug development and has interacted with regulatory authorities including the FDA, the EMA, and the Japanese Pharmaceuticals and Medical Devices Agency. She holds a Doctor of Pharmacy degree from the University of Strasbourg.
The filing also notes that Dr. Zimmermann has served as a director of Ligand Pharmaceuticals, a Nasdaq-listed biopharmaceutical company, since October 2023, and previously served as a director of Caelum Biosciences from February 2018 to October 2021 and of Inventiva S.A. from April 2021 to August 2025. The company disclosed that Dr. Zimmermann entered into its standard form of indemnification agreement, and that there are no family relationships or undisclosed arrangements associated with her appointment.
What Was Disclosed
Candel Therapeutics reported the expansion of its Board from ten to eleven directors and the appointment of Martine Zimmermann, Pharm.D., as an independent Class III director, along with her compensation terms, biographical background, and indemnification agreement.




Please wait processing your request...